324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug
The Readout Loud
00:00
Intro
This chapter explores key developments in the life sciences sector, including Genentech's closure of its cancer immunotherapy group and Pfizer's withdrawal of a sickle cell drug. It also discusses the upcoming approval of a schizophrenia treatment and includes insights on Johnson & Johnson's advancements in oncology.
Transcript
Play full episode
